scholarly article | Q13442814 |
P356 | DOI | 10.1093/JAC/48.5.727 |
P698 | PubMed publication ID | 11679564 |
P2093 | author name string | Turner J | |
Bennett PM | |||
MacGowan AP | |||
Wootton M | |||
Howe RA | |||
Salisbury V | |||
Holt HA | |||
Bowker KE | |||
Walsh TR | |||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Staphylococcus aureus | Q188121 |
pharmacokinetics | Q323936 | ||
vancomycin | Q424027 | ||
methicillin-resistant Staphylococcus aureus | Q595158 | ||
P1104 | number of pages | 4 | |
P304 | page(s) | 727-730 | |
P577 | publication date | 2001-11-01 | |
P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
P1476 | title | The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model | |
P478 | volume | 48 |
Q40542104 | Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus |
Q40326741 | In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus |
Q44758945 | Linezolid in VAP by MRSA: a better choice? |
Q37287797 | Molecular Epidemiology of a Vancomycin-Intermediate Heteroresistant Staphylococcus epidermidis Outbreak in a Neonatal Intensive Care Unit. |
Q41925060 | Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection |
Q43433837 | Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility |
Search more.